Leflunomida Farmoz (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, a key step in de novo pyrimidine synthesis. By limiting pyrimidine production, the drug curtails the proliferation of activated T‑ and B‑lymphocytes, which reduces the release of inflammatory cytokines and dampens the autoimmune response that drives rheumatoid and psoriatic arthritis.

The appropriate dose of Leflunomida Farmoz is determined by the prescribing physician based on the individual patient's disease severity, response to therapy, renal and hepatic function, and any concomitant medications. Dosage regimens are not standardized in public literature and should follow the clinician’s judgment and local prescribing guidelines.

Leflunomida Farmoz is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and embryotoxicity. Women of child‑bearing potential must use effective contraception, and the drug should not be used while breastfeeding, as it may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leflunomida Farmoz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with conventional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a different mechanism targeting pyrimidine synthesis. It may be chosen when patients cannot tolerate methotrexate or need an alternative before escalating to biologic therapies. However, leflunomide carries a distinct safety profile, including a higher risk of liver enzyme elevation and teratogenicity.

Leflunomida Farmoz should be stored at temperatures below 25 °C (77 °F). Keep the tablets in their original blister pack or container, protect them from moisture, excessive heat and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

The medication is supplied as oral tablets intended for swallowing whole with a glass of water. It is taken once daily, preferably at the same time each day, and can be taken with or without food. Patients should follow the dosing instructions provided by their healthcare professional.

The most serious adverse events include severe liver injury (jaundice, hepatic failure), bone marrow suppression leading to anemia or infections, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Early detection through regular laboratory monitoring and prompt reporting of symptoms like unexplained fatigue, yellowing of the skin or severe rash is essential.

Leflunomida Farmoz is contraindicated in pregnant women, patients with known hypersensitivity to leflunomide, and those with severe hepatic impairment. Caution is also advised for individuals with pre‑existing bone marrow disorders, uncontrolled hypertension, or active infections. The drug should be avoided in patients planning pregnancy due to its teratogenic potential.